
Roberto Ferrara/X
Apr 14, 2025, 07:18
Roberto Ferrara: Time to tailor chemo-IO in early stage NSCLC
Roberto Ferrara, Medical Oncologist,Researcher in Thoracic Oncology and Molecular Immunology at Vita-Salute San Raffaele University, posted on LinkedIn:
“Time to tailor chemo-IO in early stage NSCLC. Reconstructed individual patient data analysis shows NEOAD= PERIOP in pCR, MPR and no-MPR. PERIOP performs well in pure-MPR (1-10% RVT). While pCR or no-MPR may deserve future descalation or escalation treatment strategies, respectively.”
Authors: Antonio Nuccio et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 13:43
Apr 19, 2025, 13:05